<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=15566&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="520673" class="table-">
                
                <td>March 18, 2025, noon</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.2.12.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against BA.1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against BA.1 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.2.12.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against BA.1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against BA.1 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="396284" class="table-">
                
                <td>April 8, 2022, 9:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Titers (GMT);Change in Geometric Mean Ratio
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Titers (GMT);Change in Geometric Mean Ratio
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="389236" class="table-">
                
                <td>March 22, 2022, 10 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Ratio;Change from baseline in Geometric Mean Titers (GMT)
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Ratio;Change from baseline in Geometric Mean Titers (GMT)
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
March 18, 2025, noon	usa	Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.2.12.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against BA.1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against BA.1 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.	Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.2.12.1 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in Two Dose Group.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in One Dose Groups.;Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against B.1.351 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against BA.1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against BA.1 in Two Dose Group.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in One Dose Groups.;Geometric Mean (GM) AUC of Antibody Against Wa-1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in One Dose Groups.;Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in Two Dose Group.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.;Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
April 8, 2022, 9:30 p.m.	usa	Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Titers (GMT);Change in Geometric Mean Ratio	Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Titers (GMT);Change in Geometric Mean Ratio
March 22, 2022, 10 a.m.	usa	Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Ratio;Change from baseline in Geometric Mean Titers (GMT)	Change from baseline in Geometric Mean Fold Rise (GMFR);Change from baseline in Geometric Mean Ratio;Change from baseline in Geometric Mean Titers (GMT)